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To investigate the cost-effectiveness of screening and subsequent intervention for age-
related macular degeneration (AMD) in Japan.
Methods
The clinical effectiveness and cost-effectiveness of screening and subsequent intervention
for AMD were assessed using a Markov model. The Markov model simulation began at the
age of 40 years and concluded at the age of 90 years. The first-eye and second-eye com-
bined model assumed an annual state-transition probability, development of prodromal
symptoms, choroidal neovascularization (CNV), and reduction in visual acuity. Anti–vascu-
lar-endothelial-growth-factor (anti-VEGF) intravitreal injection therapy and photodynamic
therapy (PDT) were performed to treat CNV. Intake of supplements was recommended to
patients who had prodromal symptoms and unilateral AMD. Data on prevalence, morbidity,
transition probability, utility value of each AMD patient, and treatment costs were obtained
from published clinical reports.
Results
In the base-case analysis, screening for AMD every 5 years, beginning at the age of 50
years, showed a decrease of 41% in the total number of blind patients. The screening pro-
gram reduced the incidence of blindness more than did the additional intake of supple-
ments. However, the incremental cost-effectiveness ratio (ICER) of screening versus no
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screening was 27,486,352 Japanese yen (JPY), or 259,942 US dollars (USD) per quality-
adjusted life year (QALY). In the sensitivity analysis, prodromal symptom-related factors for
AMD had great impacts on the cost-effectiveness of screening. The lowest ICER obtained
from the best scenario was 4,913,717 JPY (46,470 USD) per QALY, which was approxi-
mately equal to the willingness to pay in Japan.
Conclusions
Ophthalmologic screening for AMD in adults is highly effective in reducing the number of
patients with blindness but not cost-effective as demonstrated by a Markov model based on
clinical data from Japan.
Introduction
Age-related macular degeneration (AMD) is the leading cause of blindness in developed coun-
tries.[1–6] In Japan, AMD ranks fourth among the causes of visual impairment, and about
700,000 patients suffer from the disease.[7, 8] Although no treatment for AMD has been avail-
able until recently, AMD is now commonly treated with anti–vascular-endothelial-growth-fac-
tor (anti-VEGF) intravitreal injection therapy and photodynamic therapy (PDT).[9] AMD
frequently develops in only one eye of an elderly person; binocular involvement of AMD is
minor[10, 11] because of slow involvement of the other eye.[12–14] Patients may be unaware
of their vision changes in daily life when only one of the two eyes is affected, because the
impairment of quality of life (QOL) may be limited. Consequently, it may be difficult to detect
early-stage AMD, particularly monocular AMD, and subsequent adequate treatment of AMD
may be delayed. In addition, treatment for AMD has economic costs to the patients and to soci-
ety, and the injections require frequent visits to medical institutions over a long period. Thus,
conclusions on the reported cost-effectiveness of therapies for AMD are not consistent.[15–17]
Early detection of AMD, however, increases the likelihood of better visual acuity results
with the improvement of treatment[18] and of detecting imaging technology[19]. Intake of
supplements is also reported to delay the onset of AMD.[20–22] For these reasons, early detec-
tion of AMD is considered important. This article addresses the cost-effectiveness of screening
for AMD in adults for the critical early detection.
Previous studies on the cost-effectiveness of AMD treatment have identified three impor-
tant factors influencing their results:[15]
1. the model selected for verification (a second-eye model, a first-eye model, or a combination
first-eye and second-eye model);[23]
2. the time horizon;[24]
3. the scope of costs (e.g., whether long-term nursing care costs or indirect costs are included).[17]
Many studies assessing the cost-effectiveness of AMD therapies have used the second-eye
model proposed by Brown.[25] Accordingly, their assumption is that therapy is not initiated
until the disease develops in the second eye (the previously unaffected eye). This model does
not always represent the actual treatment procedure. However, a smaller number of studies
have employed the first-eye and second-eye combined model,[15] which more accurately
reflects actual treatment procedure. Since screening aims at early disease detection and early
intervention based on such early detection, consideration must be given to the first eye.
Clinical- and Cost-Effectiveness of AMD Screening
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The Markov model describes repetitive events that occur over a long period. It has been
widely used in studies on cost-effectiveness.[26, 27] In fact, the Markov model has been widely
used to evaluate the cost-effectiveness of strategies to treat or prevent various ophthalmologic
diseases and is therefore the gold standard method for such economic evaluation.[28, 29] The
aim of this study was to investigate the clinical effectiveness (reduction in the number of
patients with blindness) and the cost-effectiveness (from a value-for-money perspective) of
screening and subsequent treatment of AMD in Japan. Specifically, our aim was to use a Mar-
kov model to evaluate the reduction in the incidence of blindness and the incremental cost-
effectiveness of screening for AMD and subsequent treatment of AMD.
Participants and Methods
In this study, a model was created and analyzed by using TreeAge Pro 2009 Suite (Release 1.0)
to estimate screening outcomes. The model consisted of a decision tree and a Markov model.
The decision tree was used to group adults into those receiving ophthalmologic screening (the
screened group) and those not receiving screening (the non-screened group). The strategy of
the non-screened group was considered representative of the current actual practice for AMD,
which involves visits and treatments. The Markov model of disease progression compared two
strategies: a screening strategy and non-screening strategy. The first-eye and second-eye com-
bined model was employed. The steps of disease progression were categorized by the following
six Markov states (Fig 1): normal, prodromal, moderate AMD, severe AMD, blindness, and
death. The severity of AMD was classified into one of the following three stages based on best
corrected visual acuity (VA): moderate (VA: 0.5–0.9), severe (VA: 0.1–0.4), and blindness (VA:
< 0.1). The model simulated a hypothetical Japanese cohort of 50,000 persons aged 40 years
without any eye disease, and the simulation ran until they reached 90 years of age or died
according to age-specific background mortality based on the 2009 Japan abridged life tables.
Cumulative costs of screenings and treatments and quality-adjusted life years (QALYs) were
calculated per person for the entire simulation period, using an annual discount rate of 3%.
Based on published data of incidence rates, it was assumed that the cohort would develop
prodromal symptoms and then moderate AMD. In each cycle, each patient’s disease condition
was rated as aggravated, maintained, or improved using transition probabilities. For members
of the non-screened group, the disease was detected during a coincidental consultation or con-
sultation due to subjective symptoms. For members of the screened group, the disease was
detected during a coincidental consultation, consultation due to subjective symptoms, or
screening visit. Coincidental consultations refer to visits to ophthalmologic clinics for treat-
ment of eye diseases unrelated to AMD. Consultations due to subjective symptoms refer to vis-
its to ophthalmologic clinics because of subjective symptoms. In the model, increased severity
referred to loss of vision in one or both eyes. Visits for screening began at age 50 years, occurred
once every 5 years, and ended at age 90 years (base case).
It was assumed that once AMDwas detected it was under medical control, with patients
receiving the appropriate treatments; the eyes with prodromal symptoms or AMDwere examined
periodically, the patients were advised to take supplements, and the patients received treatment
with intravitreal injection (of anti-VEGF drug) and/or PDT, depending on the stage of AMD.
Model parameters
Table 1 shows the parameters used in our model. For these parameters, clinical research data on
the Japanese population was obtained to the extent possible; if no applicable Japanese data were
available, overseas data were used. For the sensitivity analysis, the range of values for each param-
eter was set for the 95% confidence interval (CI) or ±50% from the reported baseline value.
Clinical- and Cost-Effectiveness of AMD Screening
PLOS ONE | DOI:10.1371/journal.pone.0133628 July 27, 2015 3 / 20
Model validation
To validate our model, we compared the reported numerical values (for prevalence of AMD,
incidence of unilateral AMD, and rate of blindness) with simulated values, which are described
later, for the non-screened group. To simulate the future number of AMD patients and to vali-
date the model, the number of AMD patients after controlling ages was calculated by using as a
starting point the current population, by age, in each Markov status.
Ophthalmologic screening program
It was assumed that ophthalmologists used fundus photographs in making their diagnoses.
Morbidity rate
AMD was assumed to develop in eyes with prodromal symptoms. Probabilities of the onset of
prodromal symptoms and AMD (one eye) in the Japanese population were obtained from pub-
lished reports.[30, 31, 40] When AMD developed in only one eye, the probability of AMD
occurring in the unaffected eye was quite high. The probability of AMD occurring in the
Fig 1. Basic Concepts of Markov Models for AMD. In the current study, AMD is assumed to develop from a normal eye via prodromal state. AMD is
categorized in three stages: moderate AMD, severe AMD, and blindness. VA: best corrected visual acuity.
doi:10.1371/journal.pone.0133628.g001
Clinical- and Cost-Effectiveness of AMD Screening
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Table 1. Parameter values used in the Markovmodel with ranges used for univariate sensitivity analysis.
Model parameters
group





aged 40 years normal 100% -
Age to terminate model 90 years -
Age to start screening 50 years 40, 50, 60, 70 years
Age to end screening 90 years 60, 70, 80, 90 years
Interval between screenings 5 years 1–10 years
Transition
probabilities
Normal! prodromal age 40 years 0.00% ±50%
age 45 years 0.95% ±50% [30]
age 55 years 0.13% ±50% [30]
age 65 years 0.76% ±50% [30]
age 75 years 1.40% ±50% [30]
Prodromal! moderate age 40 years 0.00% ±50%




Moderate AMD! severe AMD 37.49% ±50% [33]
Severe AMD! blindness 19.07% ±50% [33]
Epidemiology
AMD type
tAMD 40.8% 35.2%–45.3% [34]
PCV 54.7% 48.9%–60.4% [34]
RAP 4.5% - [34]










Incidence rate of presbyopia 3.00% 1%–5% [35]
Prevalence of presbyopia prodromal/moderate AMD 20.00% -
severe AMD 20.00% (in year 1 of
stage change)
20.00% (between years 1
and 3 of stage change)
Consultation rate caused by
increased severity




Moderate/severe AMD 5.00% 0.00%–50.00%
Blindness 0.00% -
Detection rate in screening
Sensitivity 80% 60%–100%
Specificity 95% 80%–100%
Utility better eye/worse eye
Normal normal/normal 1.00 -
(Continued)
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Model parameters Classification Base-case value Range for univariate
sensitivity analysis
References
normal/ prodromal 1.00 -
normal/moderate 0.92 0.87–0.97 [25]
normal/severe 0.90 0.83–0.92 [25]
normal/blindness 0.88 0.81–0.92 [25]
Prodromal prodromal/prodromal 0.97 0.92–1.00 [25]
prodromal/moderate 0.92 0.87–0.97 [25]
prodromal/severe 0.90 0.83–0.92 [25]
prodromal/blindness 0.88 0.81–0.92 [25]
Moderate AMD moderate/moderate 0.85 0.73–0.96 [36]
moderate/severe 0.83 0.73–0.85 [36]
moderate/blindness 0.81 0.71–0.85 [36]
Severe AMD severe/severe 0.57 0.46–0.85 [36]
severe/blindness 0.55 0.46–0.57 [36]
Blindness blindness/blindness 0.46 0.35–0.57 [36]
Cost
Screening 3,000 JPY ±50%
Detailed examination 13,900 JPY ±50%
Observation 4,420 JPY ±50%
Supplements (1 year) 51,360 JPY ±50%
Ranibizumab (each time for one
eye)
182,035 JPY ±50%
PDT (each time for one eye) 363,450 JPY ±50%
PDT (each time for both eyes) 540,000 JPY ±50%
Endophthalmitis 1,052,750 JPY ±50%
Discount rate 3.00% 0.00%–5.00%
Treatments
Prodromal (supplements)
Intake rate 50% 0%–100%
Rate of continuation of
supplement intake each year
90% 50%–100%
Rate of suppression of AMD 25% 0%–50% [21]




Number of observations per
year
12 6–12
Number of injections per year year 1 6 3–12
year 1 4 2–8
after year 2 2 1–3




Severe AMD (ranibizumab and
PDT)
Number of observations per
year
12 6–12
Number of injections per year year 1 6 3–12
year 2 4 2–8
(Continued)
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second eye was obtained from the literature and used in cases of prodromal stage disease being
detected in the second eye.[12–14]
Participation rate for screening
Because there is currently no concrete and consistent ophthalmologic screening program for
adults, data on the participation rates for screening and detailed examination are limited. Arbi-
trary numbers for these parameters were set in the base-case analysis and sensitivity analysis
was performed to evaluate the effect of these parameters on the model.
Although the coincidental consultation may take place in a variety of clinical settings, our
model assumed that patients visited ophthalmologic clinics with presbyopia or AMD at specific
rate. The prevalence of presbyopia in Japan is reported to be 43.8% for those aged 40 years or
older,[35] and our estimate of the annual rate of increase in presbyopia was 3%. We assumed
that 20% of those with presbyopia would visit ophthalmologic clinics and be diagnosed with
AMD. However, the probability of these assumptions was applicable only for a 1-year period
after the onset of presbyopia.
Dropout from treatment
In the early stages of AMD, patients rarely notice their symptoms, thus their motivation to con-
tinue treatment is weak, leading to some drop out of treatment. Our model assumed that
patients with prodromal symptoms (therefore at high risk for AMD) would undergo periodic
monitoring of symptoms and receive supplement therapy. Dropouts in this group were
expected to be particularly high: the rate of withdrawal was set at 50% for the first year of ther-
apy and at 10% for subsequent years. For patients with later stages of the disease, the rate of
withdrawal was set at 5%. For patients with unilateral or bilateral blindness, no withdrawal was




Model parameters Classification Base-case value Range for univariate
sensitivity analysis
References
after year 2 2 1–3
Number of PDT treatments per
year
year 1 1 1–6
after year 1 0 -




severe AMD! blindness 5% 1%–10%
moderate AMD! severe
AMD after year 1
22% 5%–40% [38]
Number of observations of each





Abbreviations: PDT (photodynamic therapy), tAMD (typical neovascular AMD), PCV (polypoidal choroidal vascularization), RAP (retinal angiomatous
proliferation).
doi:10.1371/journal.pone.0133628.t001
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Prognosis and therapy
The progression of a patient through the stages of AMD was characterized by transition proba-
bilities obtained from published reports.[33, 37, 41–48] For prodromal symptoms, supplement
intake, which reduces the incidence of AMD,[21, 49, 50] was assumed in addition to follow-up
observations.
Treatment of AMD depended on its stage and type. AMD is classified into one of three
types: typical neovascular AMD (tAMD), polypoidal choroidal vascularization (PCV), and reti-
nal angiomatous proliferation (RAP). In our model, the probability of a patient having each
type of AMD was based on previously published rates of AMD onset.[34] It was assumed that
the type of AMD affecting the second eye would be the same as that affecting the first eye. The
treatment strategies assumed in our model were in accordance with a Japanese clinical guide-
line.[51] Specifically, intravitreal injection (of ranibizumab) was administered to those with
moderately severe conditions irrespective of AMD type. For those who did not drop out of a
series of treatments, the number of injections per year was set at 6 for the first year of treat-
ment, 4 for the second year, and 2 for the third year and each subsequent year, based on actual
world data.[52] It was assumed that the treatment would maintain the visual acuity in 95% of
patients but that disease severity would increase in the remaining 5%. Beginning in the second
year of treatment, the annual transition probability—the probability of developing a more
severe stage of the disease—was assumed to be 22%.[38]
When a patient’s disease condition was severe, a patient with tAMD was assumed to
receive only intravitreal injection, and a patient with PCV or RAP was assumed to undergo
both intravitreal injection and PDT. The number of injections administered to a patient with
severe condition was assumed the same as that administered to a patient with moderate condi-
tion. PDT was performed only once, in the first year of treatment, and then never again. Since
PDT does not substantially contribute to improvement of visual acuity but rather aims pri-
marily at maintaining current visual acuity, the therapeutic prognosis of intravitreal injection
(of ranibizumab) was evaluated using outcomes obtained from published reports.[37] The
probability of a patient transitioning from severe AMD to moderate AMD in the first year of
treatment was set at 40.3%, and from severe AMD to blindness at 5%. During and after the
second year of treatment, it was assumed that the disease was severe in 95% of patients. When
blind, patients were assumed to receive no treatment but to be under observation. Figs 2 and 3
show the transition in patient health status in the first-eye and second-eye combined model
used in the study.
Clinical Effectiveness Analysis
We calculated the reduction in the rate of blindness and the future number of AMD patients
by comparing the base-case analysis values shown in Table 1 to the simulated numbers for
each screening strategy.
Costs
Our model considered only direct medical costs. Specialists estimated the costs of screening,
detailed examination required to make a definite diagnosis of AMD, tests and examinations,
and various types of treatments, based on reimbursement rates defined in fees schedules for
Japanese social health insurance. All costs were in Japanese yen (JPY) and were converted into
US dollars (USD) (2014) using Federal Reserve historical foreign exchange rates (1 US$ = ¥
105.74), accessed on the following web site: https://www.federalreserve.gov/releases/g5a/
current/.
Clinical- and Cost-Effectiveness of AMD Screening
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Utility value
The utility value for each AMD patient, or the patient’s preference-based QOL, was set at 1 for
a healthy member of the population and at 0.97 for a patient having prodromal symptoms in
both eyes. Utility data were obtained using a time trade-off (TTO) method for measuring
visual-acuity–specific utility in patients with AMD. However, since the utility value may be
somewhat reduced when visual acuity differs between the better-seeing and worse-seeing eye,
as mentioned in previous reports,[53, 54] utility value was reduced for the worse-seeing eye to
allow the worse-seeing eye to affect utility value, based on those previous reports.[54] The rea-
sonability of the utility value assumptions was also assessed by incorporating ranges in the sen-
sitivity analysis. Table 1 shows the utility value assumed for each stage of AMD.
Cost-utility analysis
We calculated an incremental cost-effectiveness ratio (ICER) using the base-case analysis val-
ues shown in Table 1, to enable comparisons of cost versus utility value for each screening
Fig 2. Detailed Markovmodel structure showing transitions in health status of both first eye and second eye without treatment. Transition
probabilities were derived from previous reports, including the Hisayama Study,[30] MARINA,[33] FOCUS[47] and PIER[48].
doi:10.1371/journal.pone.0133628.g002
Clinical- and Cost-Effectiveness of AMD Screening
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strategy. ICER was calculated using the following formula:
ICER ¼ Incremental Cost = QALY Gained
Screening program
To determine the optimal screening program, the age at which to start screening, the age at
which to end screening, and the interval between screenings were each varied within their
respective ranges shown in Table 1, and the resulting ICER was calculated.
Sensitivity analysis
One-way sensitivity analysis (one-way SA) and probabilistic sensitivity analysis (PSA) based
on 10,000 Monte Carlo simulations were performed to assess the influence of each parameter
on the base-case results.
Ethics Statement
All investigations in the current study adhered to the tenets of the Declaration of Helsinki.
Fig 3. Detailed Markovmodel structure showing transitions in health status of both first eye and second eye after treatment. Transition probabilities
were derived from previous reports, mainly ANCHOR.[37]
doi:10.1371/journal.pone.0133628.g003
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Results
Model validation
We tested the model’s external validity by comparing the model’s simulated values for the non-
screened group (prevalence of AMD in persons 40 years or older, incidence of unilateral AMD,
and incidence of blindness due to AMD in persons 40 years or older) to reported values. The
prevalence of AMD in the simulated cohort was 1.31%, which was comparable to the 1.30%
reported in the Hisayama study.[30, 31] The model’s unilateral AMD incidence of 84.1% was
comparable to the 79.3% reported in the Nagahama study.[11] The cumulative incidence of blind-
ness due to AMDwas 0.026% in the simulated cohort, which was comparable to the 0.019% esti-
mate reported by the Japan Ophthalmologists Association in 2007.[55] The model was validated,
shown to represent adequately, but not perfectly or exactly, the current epidemiologic status.
Clinical effectiveness analysis
Table 2 shows the results of clinical effectiveness in the base case. Screening interventions
reduced the rate of blindness by 41% after controlling for age (the crude reduction rate calcu-
lated by the Markov model was 37%). AMD incident rate was reduced 5% by supplement intake
subsequent to prodromal detection from screening. Fig 4 shows the reduction in rate of blind-
ness and AMD by age. Reduction effect of blindness was more apparent and occurred earlier
than did a reduction in the number of AMD patients, and the screening program reduced blind-
ness rate by more than did the additional intake of supplements. The rate of blindness decreased
more between no supplements without screening and no supplements with screening than it
did between no supplements with screening and supplements with screening (Fig 4, top).
Cost-effectiveness analysis
Table 2 also shows the results of cost-effectiveness in the base case. Comparison of the screened
group with the non-screened group revealed an incremental cost of ¥81,148, incremental utility
of 0.00295, and ICER of 27,486,352 JPY, or 259,943 USD per QALY. The willingness to pay
(WTP) in Japan, representing the threshold value of ICER for cost-effectiveness, is considered
to be 5,000,000 JPY/QALY, or 47,286 USD/QALY.[56] These results indicate that ophthalmo-
logic screening for AMD is not cost-effective.
Table 2. Base-case analysis in a simulated population.
Screened Non-screened
Clinical effectiveness
Number of people at prodromal state 13,095,310 13,049,875
Number of people with AMD 870,956 916,390
Incidence rate of AMD (%) 1.25 1.31
Proportion of patients with AMD in only one eye (%) 86.1 84.1
Number of people with blindness by AMD 7,755 13,142
Blindness rate by AMD per population (%) 0.011 0.019
Cost-effectiveness
Cost (JPY/population) 103,575 22,427
Incremental cost vs. without screening 81,148 -
Utility (QALY) 23.5630 23.5601
Incremental utility vs. without screening 0.0030 -
ICER vs. without screening (JPY/QALY) 27,486,352 -
doi:10.1371/journal.pone.0133628.t002
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Efficient screening program
The age at which to start screening, age at which to end screening, and interval between screen-
ings were each varied within their respective ranges (Table 1), and an ICER was calculated for the
screening group and for the non-screening group. For the screening group, the minimum ICER
was 15,003,591 JPY/QALY, in the model for which screening starts at age 50, occurs at 6-year
intervals, and ends at age 60 (actually ends at age 56 so that no screening would occur at age 62),
and the maximum ICER was 58,593,956 JPY/QALY, in the model for which screening starts at
age 60, occurs at 7-year intervals, and ends at age 90 (actually ends at age 88 so that no screening
would occur at age 95). In USD, the ICER range is between 141,891 USD/QALY and 554,132
USD/QALY. For all screening programs, both the incremental costs and the incremental utility
values of screening versus no screening were positive numbers. However, none of the screening
programs had an ICER less than 5,000,000 JPY, Japan’s threshold for cost-effectiveness.
Sensitivity analysis
Fig 5 is a tornado diagram showing the blindness reduction rate ranges for the 15 most effective
parameters among the 52 total parameters. The reduction rates of blindness were calculated for
Fig 4. Top: The reduction rate of blindness from age-related macular degeneration, by age. Bottom: The reduction in cumulative incidence of age-
related macular degeneration, by age.
doi:10.1371/journal.pone.0133628.g004
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the screened group as compared to the non-screened group. The dropout rate from the recursive
treatment for AMD, denoted by “sensor (moderate/severe),” had the greatest effect in our model,
resulting in blindness reduction ranging from 12.5% (+50%) to 42.6% (0%) in the sensitivity
analysis. Several factors that lacked sufficient evidence included “detailed examination,” “rate of
continuation of supplement intake every year,” “rate of supplement intake.” Furthermore,
screening participation rate might weaken other factors’ effects on reduction of blindness rate.
Fig 6 is a tornado diagram showing the ICER ranges for the 15 most effective parameters
among the 52 total parameters. ICERs were calculated for the screened group as compared to the
non-screened group. The probability of transition from the prodromal stage to moderate AMD
had the greatest effect in our model, resulting in ICER ranging from 23,552,326 JPY/QALY
(222,738 USD/QALY) (+50%) to 57,321,478 JPY/QALY (542,098 USD/QALY) (-50%) in the
sensitivity analysis. Other prodromal symptom-related factors for AMD, including “risk reduc-
tion by supplements,” “probability of transition from the prodromal stage to moderate disease in
the second eye,” and “cost of supplements” also had major effects on cost-effectiveness. When it
was assumed that the drug was switched from ranibizumab to bevacizumab (but with the same
therapeutic effect), the ICER decreased to 19,906,587 JPY/QALY (188,260 USD/QALY). In a
best-case scenario for cost-effectiveness, assuming that a patient in the prodromal stage of AMD
was followed up once annually, supplements cost 0 JPY, and bevacizumab was used, the ICER
decreased to 4,913,717 JPY/QALY (46,470 USD/QALY), approximately equal to the WTP in
Japan, while the prophylactic effect against future blindness was maintained at the same level.
Probabilistic sensitivity analysis
In Fig 7, the results of PSA are presented graphically. The 10.4% of simulation results located
in quadrant 1 are below the WTP threshold of 5,000,000 JPY. The screening program was
more effective than the no-screening option in 82.8% of the results, although screening was
dominated by no-screening in the remaining 17.2% of the results.
Fig 5. Tornado diagram showing one-way sensitivity analysis targeting reduction of blindness rate as
the outcome. The 15 most effective parameters of the 52 total parameters are shown.
doi:10.1371/journal.pone.0133628.g005
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Discussion
The screening program reduced both the rate of blindness caused by AMD and the cumulative
incidence rate of AMD. However, the decrease in the rate of AMD-caused blindness was more
apparent and occurred earlier than did the decrease in the incidence of AMD. This compara-
tive success might derive from current medical intervention’s ability to only ameliorate the
symptoms or delay the progression of the disease rather than eliminate the disease itself. The
screening program evaluated in this study reduced by 41% the cumulative number of patients
to suffer blindness from AMD. The reduction is as compared to the non-screening population
and assumes current medical intervention with intravitreal injection of inhibitors of vascular
endothelial growth factor (VEGF). Without anti-VEGF drug therapy, the reduction would be
much greater, because, since the introduction of intravitreally injected anti-VEGF in 2006, the
incidence of legal blindness from AMD has already fallen to half the previous baseline inci-
dence rate.[57] The screening program reduced the blindness rate by more than did additional
intake of supplements. This comparative findings is confirmed by the rate of blindness decreas-
ing more between no supplement without screening and no supplement with screening than it
did between no supplement without screening and supplement without screening (Fig 4, bot-
tom). The screening program’s greater effectiveness than supplement intake has not been well
discussed until now. This finding should be confirmed in future discussion of early detection
approaches.
Previous studies on the cost-effectiveness of ophthalmologic treatments have frequently
used the second-eye model.[17, 23, 43, 58–60]. However, the following assumptions of the sec-
ond-eye model are not necessarily adequate to the study of cost-effectiveness of the AMD
screening program:
Fig 6. Tornado diagram showing one-way sensitivity analysis targeting incremental cost-
effectiveness ratio (ICER) as the outcome. The 15 most effective parameters of the total 52 parameters
are shown.
doi:10.1371/journal.pone.0133628.g006
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1. unilateral AMD assumed not to be treated, whereas in reality, many patients with unilateral
AMD (about 80% of patients with AMD suffer from unilateral disease[11]) are treated;
2. the worse eye in bilateral AMD assumed not to be treated, whereas in actual clinical settings,
both of the affected eyes are frequently treated; and
3. treatment of the worse eye assumed to be effective but not improving patients’QOL,
whereas in reality, many patients are at least somewhat satisfied with improvement in their
worse eyes. Recent studies have reported the worse-seeing eye to have a stronger influence
on vision-related QOL than is generally assumed.[54, 61]
Therefore, a first-eye and second-eye combined model, which has been used infrequently,
[23, 24] was used in this study.
Some published studies included non-medical costs (such as the cost of long-term care) in
the direct costs to be evaluated,[23, 37, 58, 62] while Hurley, et al. indicated that cost-effective-
ness is greater when indirect long-term care costs are included.[17] Whether or not indirect
long-term care costs should be included in our present analysis was an important issue. We
decided not to include these costs in our study, because the costs depend on how the screening
program is conducted and where the targeted population is located. If we were to include these
costs, the results would be even more cost-ineffective—costs would be higher. Furthermore,
the sensitivity analysis showed that the cost of screening had little effect on cost-effectiveness.
The base-case analysis, shown in Table 2, demonstrated that the screening program evalu-
ated in this study reduced the cumulative number of patients with blindness by 41%. Screening
for AMD, however, was not cost-effective, because the ICER was above the threshold WTP
Fig 7. Probabilistic sensitivity analysis of cost-effectiveness analysis for the screening program for age-relatedmacular degeneration.
doi:10.1371/journal.pone.0133628.g007
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estimated for Japan. A major factor contributing to this cost-ineffectiveness finding may be the
unilaterality of the disease. In our model, patients with unilateral AMD at age 90 accounted for
84.8% of all AMD patients in the screened group and 82.7% of all AMD patients in the non-
screened group. The utility value, or QALY, of these patients would not be improved even by
expensive treatments such as anti-VEGF drugs for worse eyes, because QALY is defined by the
condition of the better eye (the unaffected eye).[25] In this study, we incorporated the real-life
situation, allowing the worse eye to affect utility value, by reducing utility values when visual
acuity differed between the better and the worse eye. In the future, cost-utility analysis using
utility values based on actual TTO methods should be incorporated when the eyes of an AMD
patient differ in visual acuity. Further study is needed to strengthen the opinion we have
derived from this study’s results.
In this study, we relied on data regarding treatment mainly from reports of ideal random-
ized controlled trials with two-year follow-up periods, because they were the only ones avail-
able. Recently, outcomes from actual clinics with relatively long follow-up periods have been
reported.[63] Using the newly available data may worsen the cost-effectiveness result, because
visual acuity was reported to decrease after the first two years and to be even worse than base-
line after four years.
One-way sensitivity analysis revealed that the probability of a patient’s transition to AMD,
the prodromal symptom-related factors (including the preventive effect of supplement intake
and the cost of supplements), and utility values had the greatest effects on the model, but those
effects were not sufficiently large to make screening intervention cost-effective. In addition, dis-
count rates also affected the cost-effectiveness of screening, because there is a long interval of
time between screening and the confirmation of its effectiveness.[24] Accordingly, it is desir-
able to use a common discount rate across studies that compare similar types of medical proce-
dures; as a result, we employed 3% in this study. With regard to utility values, when the fellow
eyes of normal or prodromal eyes is affected by AMD (when better-seeing eye is normal or pro-
dromal, while worse-seeing eye is blind, sever AMD or moderate AMD), they impacted the
results. Although previous reports have paid little attention to the phenomenon, our results
showed that such difference in utility values when the two eyes are in different stages should be
considered. Further research on such differing utility values when the two eyes are in different
stages should be incorporated in studies of the cost-effectiveness of treatment for one-eye–
dominant disease.
This study suggests that factors regarding treatment and progression in early stages of AMD
are important, influencing the analysis of cost-effectiveness. This may be because, as shown in
the Table 2, screening remarkably increases detection of the prodromal stage of AMD. The
cost of intravitreal injection of ranibizumab also had an impact. When bevacizumab was
substituted for ranibizumab and both drugs were assumed to have the same therapeutic effects,
the ICER decreased only to 19,906,587 JPY/QALY (188,260 USD/QALY). Thus, screening only
for AMD is not cost-effective.
When screening for AMD, however, other vision-threatening ocular diseases, including
glaucoma and diabetic retinopathy, can be detected. A comprehensive approach to ocular dis-
ease screening, in which AMD is one of several diseases that could be detected, may yield better
cost-effectiveness, because single screenings for other ocular diseases are reported to be cost-
effective.[64] On the other hand, sensitivity analysis revealed that screening cost had only a
limited effect on ICER. In other words, even though the incremental cost of medical examina-
tion in the screening is low, particularly when no additional screening procedure is conducted
to detect AMD, the cost-effectiveness of screening will not be much improved. The cost-effec-
tiveness of both AMD screening included in a comprehensive ocular disease screening and an
entirely separate AMD screening is not high.
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Conclusion
We evaluated the clinical effectiveness and cost-effectiveness of ophthalmologic screening for
AMD in adults using a Markov model based on clinical data from Japan. In evaluating the
AMD screening program from the viewpoint of clinical effectiveness (reduction in the number
of patients with blindness) and cost-effectiveness (from a value-for-money perspective), our
results indicate that the screening program is highly effective in reducing the number of
patients with blindness but not cost-effective. The PSA results confirm that the screening pro-
gram is beneficial in terms of health gain in most cases but that its cost-effectiveness is low
given the present ICER threshold (WTP). Although parameter uncertainty has a great effect on
analysis of the results, further epidemiological and prognostic knowledge about AMD would
lead to more robust cost-effectiveness research.
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